SABRATEK TAILORING SEAMLESS MULTI-THERAPY INFUSION SYSTEM SALES GROWTH STRATEGY TO ALTERNATE-SITE MARKET; COMPANY EXPECTS TO NET $27.1 MIL. IN PUBLIC OFFERING
This article was originally published in The Gray Sheet
Executive Summary
Sabratek Corporation is hoping that its products to facilitate the treatment of patients in alternate-site settings will deliver a seamless revenue stream for the firm. To address the need for "cost-effective movement of patients along the continuum of alternate-site care," the company has developed the Seamless Delivery System of "software based infusion devices and related interactive information system," the firm says in a preliminary prospectus for an initial public offering.